- Previous Close
33.650 - Open
34.100 - Bid 33.750 x --
- Ask 34.000 x --
- Day's Range
33.350 - 34.100 - 52 Week Range
27.700 - 45.850 - Volume
79,640 - Avg. Volume
186,665 - Market Cap (intraday)
16.31B - Beta (5Y Monthly) 0.74
- PE Ratio (TTM)
16.40 - EPS (TTM)
2.070 - Earnings Date Oct 25, 2024
- Forward Dividend & Yield 1.54 (4.57%)
- Ex-Dividend Date Sep 20, 2024
- 1y Target Est
49.90
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. The company offers ophthalmology products consisting intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. It also offers sodium hyaluronate injection, medical chitosan, sodium hyaluronate gel, sodium hyaluronate gel, anti adhesion, and burn wound related products. In addition, the company provides injectors, scalpels, and suture needles. Further, it offers medical aesthetics products comprising Matrifill, a first-generation hyaluronic acid (HA) dermal filler, which is a mono-phase sodium hyaluronate gel for injection; Janlane, a second-generation HA dermal filler for dynamic filling function; Hyalumatrix, a third-generation HA dermal filler that offers precise embellishment function; genetic-engineering preparations for epidermal repair; and radio frequency devices and laser equipment. Additionally, the company is involved in the research and development of biological engineering and pharmaceutical products, as well as in the provision of related technology transfer, and consultation services; sale of professional life and home cosmetology machines; and manufacture and sale of biological reagents, biologicals and biological materials, and other machines and accessories. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. Shanghai Haohai Biological Technology Co., Ltd. was founded in 2007 and is headquartered in Shanghai, China.
www.3healthcare.comRecent News: 6826.HK
View MorePerformance Overview: 6826.HK
Trailing total returns as of 10/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6826.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6826.HK
View MoreValuation Measures
Market Cap
16.17B
Enterprise Value
13.64B
Trailing P/E
16.25
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.66
Price/Book (mrq)
1.26
Enterprise Value/Revenue
4.57
Enterprise Value/EBITDA
23.42
Financial Highlights
Profitability and Income Statement
Profit Margin
16.25%
Return on Assets (ttm)
3.63%
Return on Equity (ttm)
6.94%
Revenue (ttm)
2.75B
Net Income Avi to Common (ttm)
446.17M
Diluted EPS (ttm)
2.070
Balance Sheet and Cash Flow
Total Cash (mrq)
2.74B
Total Debt/Equity (mrq)
7.01%
Levered Free Cash Flow (ttm)
94.46M